ONCOmmunity

Erlotinib treatment in patients with advanced lung adenocarcinoma with CISH-positive and CISH-negative EGFR gene alterations

By: Hou MM, Huang SF, Kuo HP, Yang CT, Tsai YH, Yu CT, Lin HC, Chen CH, Wang CL, Chung FT, Hsieh JJ, Hsu T, Cheng HY, Ou LY, Wang HM, Lin YC, Chang NJ, Chang JW.

Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, 5 Fu-Shin Street, Kwei-Shan, Taoyuan 333, Taiwan, R.O.C.
Anticancer Res. 2012 Mar; 32(3):1107-12.

Abstract

Background

Epidermal growth factor receptor (EGFR) positivity as assessed by chromogenic in situ hybridization (CISH) has been demonstrated to be associated with EGFR mutation status. This study was conducted to compare the responsiveness of CISH-positive and CISH-negative lung adenocarcinomas to erlotinib.

Patients and Methods

Patients received erlotinib (150 mg/day) alone until disease progression or intolerable toxicity. EGFR gene status was examined by CISH. The response rate (RR), progression-free survival (PFS), overall survival (OS) and toxicity profiles were assessed.

Results

Thirty-one patients underwent response evaluations and CISH analyses, 12 of whom harboured CISH-positive adenocarcinomas. The overall RR (p=0.035), median PFS (p=0.091) and median OS (p=0.408) were higher in the CISH-positive group. No difference in toxicity profiles was observed between these two groups.

Conclusion

EGFR status as assessed by CISH can predict the response to erlotinib in patients with advanced lung adenocarcinoma.

PMID: 22399641 [PubMed - indexed for MEDLINE] Source: National Library of Medicine.